ATE477268T1 - Zusammensetzungen zur behandlung von magen-darm- störungen - Google Patents
Zusammensetzungen zur behandlung von magen-darm- störungenInfo
- Publication number
- ATE477268T1 ATE477268T1 AT07011869T AT07011869T ATE477268T1 AT E477268 T1 ATE477268 T1 AT E477268T1 AT 07011869 T AT07011869 T AT 07011869T AT 07011869 T AT07011869 T AT 07011869T AT E477268 T1 ATE477268 T1 AT E477268T1
- Authority
- AT
- Austria
- Prior art keywords
- disorders
- constipation
- conditions
- dyspepsia
- functional
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K14/245—Escherichia (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US44309803P | 2003-01-28 | 2003-01-28 | |
US47128803P | 2003-05-15 | 2003-05-15 | |
US51946003P | 2003-11-12 | 2003-11-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE477268T1 true ATE477268T1 (de) | 2010-08-15 |
Family
ID=32854294
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT04706011T ATE365174T1 (de) | 2003-01-28 | 2004-01-28 | Zusammensetzungen zur behandlung von gastrointestinalen störungen |
AT07011869T ATE477268T1 (de) | 2003-01-28 | 2004-01-28 | Zusammensetzungen zur behandlung von magen-darm- störungen |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT04706011T ATE365174T1 (de) | 2003-01-28 | 2004-01-28 | Zusammensetzungen zur behandlung von gastrointestinalen störungen |
Country Status (29)
Country | Link |
---|---|
US (3) | US20040266989A1 (de) |
EP (3) | EP2246360B1 (de) |
JP (3) | JP4584911B2 (de) |
KR (2) | KR101227626B1 (de) |
CN (2) | CN101787073B (de) |
AT (2) | ATE365174T1 (de) |
AU (2) | AU2004210161B2 (de) |
BE (1) | BE2013C032I2 (de) |
BR (2) | BR122018074353B8 (de) |
CA (1) | CA2514507C (de) |
CY (5) | CY1110905T1 (de) |
DE (2) | DE602004028678D1 (de) |
DK (3) | DK2246360T3 (de) |
ES (3) | ES2285417T3 (de) |
FR (2) | FR13C0029I2 (de) |
HK (1) | HK1078768A1 (de) |
HU (1) | HUS1300022I1 (de) |
IL (2) | IL169863A (de) |
LT (1) | LTC1594517I2 (de) |
LU (2) | LU92200I2 (de) |
MX (1) | MXPA05008097A (de) |
NL (1) | NL300593I2 (de) |
NO (2) | NO334112B1 (de) |
NZ (2) | NZ570134A (de) |
PT (3) | PT1594517E (de) |
RU (2) | RU2353383C2 (de) |
SG (2) | SG192300A1 (de) |
SI (3) | SI1594517T1 (de) |
WO (1) | WO2004069165A2 (de) |
Families Citing this family (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2539132T3 (es) | 2001-03-29 | 2015-06-26 | Synergy Pharmaceuticals, Inc. | Agonistas del receptor de guanilato ciclasa para el tratamiento de inflamación tisular y carcinogénesis |
US7371727B2 (en) * | 2003-01-28 | 2008-05-13 | Microbia, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
DE602004028678D1 (de) * | 2003-01-28 | 2010-09-23 | Ironwood Pharmaceuticals Inc | Zusammensetzungen zur Behandlung von Magen-Darm-Störungen |
US7304036B2 (en) | 2003-01-28 | 2007-12-04 | Microbia, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
US20060281682A1 (en) * | 2003-01-28 | 2006-12-14 | Currie Mark G | Methods and compositions for the treatment of gastrointestinal disorders |
US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
US7494979B2 (en) * | 2003-06-13 | 2009-02-24 | Ironwood Pharmaceuticals, Inc. | Method for treating congestive heart failure and other disorders |
PT1644021E (pt) | 2003-06-13 | 2013-01-30 | Ironwood Pharmaceuticals Inc | Métodos e composições para o tratamento de distúrbios gastrointestinais |
US20050266028A1 (en) * | 2004-05-25 | 2005-12-01 | University Of Georgia Research Foundation, Inc. | Compositions and methods for modulating an immune response |
EP1813271A4 (de) * | 2004-10-26 | 2008-05-21 | Ajinomoto Kk | Mittel zur prävention/behandlung von viszeralen schmerzen |
CA2619650A1 (en) * | 2005-08-19 | 2007-02-22 | Microbia, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
CA2625447C (en) | 2005-09-29 | 2015-06-09 | Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. | Compositions and methods for stimulating gastrointestinal motility |
WO2007101161A2 (en) * | 2006-02-24 | 2007-09-07 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
EP2650303A1 (de) * | 2007-02-26 | 2013-10-16 | Ironwood Pharmaceuticals, Inc. | Verfahren und Zusammensetzungen zur Behandlung von Herzinsuffizienz und anderen Erkrankungen |
WO2008137318A1 (en) * | 2007-05-04 | 2008-11-13 | Ironwood Pharmaceuticals, Inc. | Compositions and methods for treating disorders associated with salt or fluid retention |
US8969514B2 (en) * | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
WO2008151257A2 (en) | 2007-06-04 | 2008-12-11 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
AU2009256156B2 (en) | 2008-06-04 | 2014-09-18 | Bausch Health Ireland Limited | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
WO2009149279A2 (en) | 2008-06-04 | 2009-12-10 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
WO2010005515A2 (en) * | 2008-06-30 | 2010-01-14 | Ironwood Pharmaceuticals Incorporated | Protein expression methods |
WO2010009319A2 (en) | 2008-07-16 | 2010-01-21 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders |
SI2328601T1 (sl) * | 2008-08-15 | 2020-08-31 | Ironwood Pharmaceuticals, Inc. | Linaklotid vsebujoče formulacije za oralno dajanje |
CA2743172A1 (en) | 2008-11-19 | 2010-05-27 | Forest Laboratories Holdings Limited | Crystalline form of linaclotide |
AU2009322285B2 (en) * | 2008-12-03 | 2016-07-28 | Bausch Health Ireland Limited | Formulations of guanylate cyclase C agonists and methods of use |
EP2417152B1 (de) | 2009-04-10 | 2013-10-02 | Corden Pharma Colorado, Inc. | Verfahren zur isolierung von linaclotid |
WO2011017502A2 (en) * | 2009-08-06 | 2011-02-10 | Ironwood Pharmaceuticals, Inc. | Linaclotide-containing formulations for oral administration |
RU2012109415A (ru) | 2009-08-13 | 2013-09-20 | Айронвуд Фармасьютикалз, Инк. | Способ модуляции фармакодинамического эффекта перорально вводимых агонистов рецептора гуанилатциклазы |
WO2011057272A1 (en) | 2009-11-09 | 2011-05-12 | Ironwood Pharmaceuticals, Inc. | Treatments for gastrointestinal disorders |
KR20120103689A (ko) * | 2009-12-07 | 2012-09-19 | 아이언우드 파마슈티컬스, 인코포레이티드 | 위장 장애의 치료 |
WO2011103311A2 (en) | 2010-02-17 | 2011-08-25 | Ironwood Pharmaceuticals, Inc | Treatments for gastrointestinal disorders |
WO2011145062A1 (en) | 2010-05-21 | 2011-11-24 | Link Research & Grants Corporation | Treatment of tinnitus and related auditory dysfunctions |
WO2011156453A2 (en) | 2010-06-09 | 2011-12-15 | Combimab, Inc. | Therapeutic peptides |
CA2808091C (en) | 2010-08-11 | 2019-05-21 | Ironwood Pharmaceuticals, Inc. | Stable formulations of linaclotide |
US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
CA2810243C (en) | 2010-09-15 | 2021-04-20 | Synergy Pharmaceuticals Inc. | Formulations of guanylate cyclase c agonists and methods of use |
WO2012155114A1 (en) | 2011-05-11 | 2012-11-15 | Ironwood Pharmaceuticals, Inc. | Peptides derived from uroguanylin and their use in gastrointestinal disorders |
CA2835624A1 (en) | 2011-05-11 | 2012-11-15 | Ironwood Pharmaceuticals, Inc. | Treatments for gastrointestinal disorders |
US9617305B2 (en) | 2011-06-08 | 2017-04-11 | Ironwood Pharmaceuticals, Inc. | Treatments for gastrointestinal disorders |
US9527887B2 (en) | 2011-06-08 | 2016-12-27 | Ironwood Pharmaceutical, Inc. | Treatments for gastrointestinal disorders |
MD480Z (en) * | 2011-07-07 | 2012-09-30 | Elvira Andon | Method for treating acute ulcerative nonspecific colitis |
WO2013025969A1 (en) | 2011-08-17 | 2013-02-21 | Ironwood Pharmaceuticals, Inc. | Treatments for gastrointestinal disorders |
EA022546B1 (ru) * | 2011-09-28 | 2016-01-29 | Федеральное Государственное Бюджетное Учреждение Науки Институт Биоорганической Химии Им. Академиков М.М. Шемякина И Ю.А. Овчинникова Российской Академии Наук | Способ торможения роста карциномы эрлиха у лабораторного животного |
JP2016521249A (ja) * | 2012-07-12 | 2016-07-21 | フォレスト ラボラトリーズ ホールディングス リミテッド | リナクロチド組成物 |
RU2528641C2 (ru) * | 2012-08-22 | 2014-09-20 | Государственное бюджетное образовательное учреждение высшего профессионального образования "Воронежская государственная медицинская академия им. Н.Н. Бурденко" Министерства здравоохранения и социального развития Российской Федерации | Способ лечения больных с синдромом диспепсии в сочетании с избыточной массой тела |
CN102875655B (zh) * | 2012-09-29 | 2014-12-17 | 深圳翰宇药业股份有限公司 | 一种合成利那洛肽的方法 |
EP2950803A1 (de) | 2013-01-30 | 2015-12-09 | Sandoz AG | Kristalline form von linaclotid |
JP2016514671A (ja) | 2013-03-15 | 2016-05-23 | シナジー ファーマシューティカルズ インコーポレイテッド | グアニル酸シクラーゼのアゴニストおよびその使用 |
CN105979959B (zh) | 2013-08-09 | 2021-11-30 | 阿德利克斯公司 | 用于抑制磷酸盐转运的化合物和方法 |
ES2947591T3 (es) * | 2015-05-01 | 2023-08-11 | Ironwood Pharmaceuticals Inc | Composiciones para la limpieza del colon y el tratamiento de trastornos gastrointestinales |
EP3430056A4 (de) * | 2016-03-15 | 2019-11-20 | The Regents of the University of California | Verfahren und zusammensetzungen für die behandlung und vorbeugung von mit alpha-8-beta-1-integrin-assoziierten krankheiten |
CN107929718A (zh) * | 2017-10-19 | 2018-04-20 | 南京星银药业集团有限公司 | Glp‑1类似物及gc‑c受体激动剂组合物缓释制剂及其制备方法 |
JP2022503807A (ja) * | 2018-10-23 | 2022-01-12 | エービーケー バイオメディカル インコーポレイテッド | 輸送装置 |
CN109467606A (zh) * | 2018-11-15 | 2019-03-15 | 大连理工大学 | 一种大肠杆菌肠毒素STa-LTB-STb融合蛋白及其编码基因和应用 |
WO2020237096A1 (en) | 2019-05-21 | 2020-11-26 | Ardelyx, Inc. | Combination for lowering serum phosphate in a patient |
RU2712761C1 (ru) * | 2019-07-02 | 2020-01-31 | Федеральное государственное бюджетное научное учреждение "Томский национальный исследовательский медицинский центр Российской академии наук" (Томский НИМЦ) | Средство для стимуляции регенерации эндотелия легких при сочетании метаболического синдрома и хронической обструктивной болезни легких |
CN111265653B (zh) * | 2020-02-09 | 2023-05-09 | 华中科技大学同济医学院附属协和医院 | 心房利钠肽在制备炎症性肠病治疗药物中的应用 |
US20230035733A1 (en) * | 2020-03-26 | 2023-02-02 | Dusa Pharmaceuticals, Inc. | Management of dermal neurofibromatosis lesions |
WO2023144292A1 (en) | 2022-01-28 | 2023-08-03 | Fresenius Kabi Ipsum S.R.L. | Process for the preparation of linaclotide |
Family Cites Families (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US73628A (en) * | 1868-01-21 | mitchell | ||
US152868A (en) * | 1874-07-07 | Improvement in type-setting machines | ||
US258687A (en) * | 1882-05-30 | Grain-binder | ||
US32684A (en) * | 1861-07-02 | Stump-extkactob | ||
US232013A (en) * | 1880-09-07 | Henry h | ||
US121961A (en) * | 1871-12-19 | Improvement in devices for supporting pipe-cores | ||
US266989A (en) * | 1882-11-07 | Automatic fire | ||
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
US6342373B1 (en) * | 1983-11-21 | 2002-01-29 | Ucp Gen-Pharma Ag | Process for preparing recombinant eglin, protease inhibitor |
IT1217123B (it) | 1987-02-05 | 1990-03-14 | Rotta Research Lab | Derivati otticamente attivi dell acido 5 pentilammino 5 oxo pentanoico r ad attivita antagonista della colecistochinina e procedimento per la loro preparazione |
GB2209937B (en) | 1987-09-21 | 1991-07-03 | Depiopharm S A | Water insoluble polypeptides |
CH679207A5 (de) | 1989-07-28 | 1992-01-15 | Debiopharm Sa | |
CA2046830C (en) | 1990-07-19 | 1999-12-14 | Patrick P. Deluca | Drug delivery system involving inter-action between protein or polypeptide and hydrophobic biodegradable polymer |
HUT64023A (en) | 1991-03-22 | 1993-11-29 | Sandoz Ag | Process for producing aminoguanidine derivatives and pharmaceutical compositions comprising such compounds |
FR2674849B1 (fr) | 1991-04-02 | 1994-12-23 | Logeais Labor Jacques | Nouveaux derives de n-cyclohexyl benzamides ou thiobenzamides, leurs preparations et leurs applications en therapeutique. |
CH683149A5 (fr) | 1991-07-22 | 1994-01-31 | Debio Rech Pharma Sa | Procédé pour la préparation de microsphères en matériau polymère biodégradable. |
US5140102A (en) | 1991-09-23 | 1992-08-18 | Monsanto Company | Pentadecapeptide, guanylin, which stimulates intestinal guanylate cyclase |
RU2194760C2 (ru) * | 1991-12-02 | 2002-12-20 | Кор Терапьютикс, Инк. | Иммуноглобулиновый полипептид, его фрагмент, композиция, штамм гибридных культивируемых клеток, способ получения полипептида |
US5824645A (en) | 1991-12-30 | 1998-10-20 | Neurex Corporation | Method of treating inflammation |
DE69225499T2 (de) | 1991-12-30 | 1999-02-04 | Neurex Corp | Methoden zur erzeugung von analgesie und zur verstärkung von opiat-analgesie |
GB9211268D0 (en) | 1992-05-28 | 1992-07-15 | Ici Plc | Salts of basic peptides with carboxyterminated polyesters |
US5969097A (en) | 1992-06-23 | 1999-10-19 | G. D. Searle & Co. | Human guanylin |
US5672659A (en) | 1993-01-06 | 1997-09-30 | Kinerton Limited | Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides |
AU680650B2 (en) | 1993-01-06 | 1997-08-07 | Ipsen Manufacturing Ireland Limited | Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides |
US5395490A (en) * | 1993-05-14 | 1995-03-07 | Intertec, Ltd. | Method for treating materials by the application of electromagnetic energy at resonant absorption frequencies |
EP0734264B1 (de) * | 1993-10-26 | 2004-02-18 | Thomas Jefferson University | Verbindungen die kolorektale krebszellen spezifisch binden und verfahren für ihre herstellung |
US5489670A (en) * | 1993-10-29 | 1996-02-06 | G. D. Searle & Co. | Human uroguanylin |
US5610145A (en) | 1994-04-15 | 1997-03-11 | Warner-Lambert Company | Tachykinin antagonists |
US5612052A (en) | 1995-04-13 | 1997-03-18 | Poly-Med, Inc. | Hydrogel-forming, self-solvating absorbable polyester copolymers, and methods for use thereof |
US6054429A (en) | 1996-03-08 | 2000-04-25 | Elan Pharmaceuticals, Inc. | Epidural method of producing analgesia |
US5795864A (en) | 1995-06-27 | 1998-08-18 | Neurex Corporation | Stable omega conopetide formulations |
DK0835126T3 (da) | 1995-06-27 | 2003-07-14 | Elan Pharm Inc | Sammensætninger og formuleringer til fremstilling af analgesimidler og til hamning af fremadskridende neuropatiske amertelidelser |
AP9801237A0 (en) | 1995-11-24 | 1998-06-30 | Smithkline Beecham Farm S P A | Quinoline derivatives. |
GB9524104D0 (en) | 1995-11-24 | 1996-01-24 | Smithkline Beecham Spa | Novel compounds |
CA2250981C (en) | 1996-04-23 | 2002-07-02 | Kinerton Limited | Acidic polylactic polymers |
US6589750B2 (en) | 1997-02-20 | 2003-07-08 | Institut Pasteur | Therapeutic use of the SMR1 protein, the SMR1 maturation products, specifically the QHNPR pentapeptide as well as its biologically active derivatives |
US6333354B1 (en) | 1997-02-28 | 2001-12-25 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Synergistic combination of PDE inhibitors and adenylate cyclase agonists or guanyl cyclyse agonists |
US5893985A (en) | 1997-03-14 | 1999-04-13 | The Lincoln Electric Company | Plasma arc torch |
NZ329807A (en) | 1997-04-23 | 2000-07-28 | Pfizer | NK-1 receptor antagonists and P receptor antagonists 2-Diarylmethyl-3-amino-1-azabicyclo[2.2.2]octane derivatives and amino substituted N-containing rings as agents for treating irritable bowel syndrome |
JP2001516765A (ja) | 1997-09-12 | 2001-10-02 | ヴォルフ ゲオルグ フォースマン | 真性糖尿病及び肥満の治療のための組成物 |
US20010006972A1 (en) | 1998-04-21 | 2001-07-05 | Stephen A. Williams | Nk-1 receptor antagonists for the treatment of symptoms of irritable bowel syndrome |
IT1304152B1 (it) | 1998-12-10 | 2001-03-08 | Mediolanum Farmaceutici Srl | Composizioni comprendenti un peptide ed acido polilattico-glicolicoatte alla preparazione di impianti sottocutanei aventi un prolungato |
EP1185294B1 (de) | 1999-06-23 | 2005-03-30 | Institut Pasteur | Peptide zur behandlung von beeinträchtigten zwischenmenschlischen störungen und verhaltenstörungen |
EP1204429B1 (de) | 1999-08-18 | 2003-10-29 | Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. | Formulierung zur verzögerten freisetzung von peptiden |
SE9903291D0 (sv) | 1999-09-15 | 1999-09-15 | Astra Ab | New process |
JP2003516316A (ja) | 1999-10-06 | 2003-05-13 | ファルマシア コーポレイション | 腸癌阻止剤としてのウログアニリン |
WO2001032180A2 (en) | 1999-11-01 | 2001-05-10 | Rodeva Limited | Composition for treatment of constipation and irritable bowel syndrome |
AUPQ514600A0 (en) | 2000-01-18 | 2000-02-10 | James Cook University | Brain injury treatment |
AU3580001A (en) | 2000-03-01 | 2001-09-12 | University College London | Modulators of the endocannabinoid uptake and of the vallinoid receptors |
PT1216707E (pt) | 2000-12-22 | 2005-06-30 | Pasteur Institut | Novas utilizacoes terapeuticas para um smr-1-peptideo |
JP2004521123A (ja) | 2001-02-02 | 2004-07-15 | ファルマシア・コーポレーション | 腸癌阻害のためのウログアニリンおよびシクロオキシゲナーゼ−2阻害薬の組合わせ |
ES2539132T3 (es) * | 2001-03-29 | 2015-06-26 | Synergy Pharmaceuticals, Inc. | Agonistas del receptor de guanilato ciclasa para el tratamiento de inflamación tisular y carcinogénesis |
AU2002311556A1 (en) | 2001-03-30 | 2002-10-15 | University Of Copenhagen | Compositions and methods for modulating guanylyl cyclase signaling receptor (gc-c) activity and for treating meniere's disease |
MY134211A (en) | 2001-05-18 | 2007-11-30 | Smithkline Beecham Corp | Novel use |
WO2002098912A2 (de) * | 2001-06-05 | 2002-12-12 | Yalcin Cetin | Luftseitig verabreichte guanylat cyclase c liganden für atemwegserkrankungen |
FR2830451B1 (fr) | 2001-10-09 | 2004-04-30 | Inst Nat Sante Rech Med | Utilisation de peptides analogues de la thymuline(pat)pour la fabrication de medicaments contre la douleur |
EP1321142A1 (de) | 2001-12-21 | 2003-06-25 | Novartis AG | Feste orale Zubereitung mit Tegaserod |
US20040121961A1 (en) | 2002-02-04 | 2004-06-24 | Jaime Masferrer | Uroguanylin and cyclooxygenase-2 inhibitor combinations for inhibition of intestinal cancer |
US20030232013A1 (en) | 2002-02-22 | 2003-12-18 | Gary Sieckman | Therapeutic and diagnostic targeting of cancers cells with tumor homing peptides |
AU2003224644A1 (en) | 2002-02-27 | 2003-09-09 | The Government Of The United States Of America, Represented By The Secretary, Department Of Healtan | Conjugates of ligand, linker and cytotoxic agent and related compositions and methods of use |
JP2005526079A (ja) | 2002-03-15 | 2005-09-02 | サイプレス バイオサイエンス, インコーポレイテッド | 内蔵痛症候群を処置するためのneおよび5−ht再取り込み阻害剤 |
DE60327315D1 (de) | 2002-05-17 | 2009-06-04 | Tioga Pharmaceuticals Inc | Verwendung von verbindungen, die als selektive opiat-rezeptor-modulatoren wirksam sind |
US7304036B2 (en) | 2003-01-28 | 2007-12-04 | Microbia, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
US20060281682A1 (en) | 2003-01-28 | 2006-12-14 | Currie Mark G | Methods and compositions for the treatment of gastrointestinal disorders |
DE602004028678D1 (de) | 2003-01-28 | 2010-09-23 | Ironwood Pharmaceuticals Inc | Zusammensetzungen zur Behandlung von Magen-Darm-Störungen |
US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
US7371727B2 (en) * | 2003-01-28 | 2008-05-13 | Microbia, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
US8206704B2 (en) | 2003-02-10 | 2012-06-26 | Thomas Jefferson University | Use of GCC ligands |
CA2619650A1 (en) | 2005-08-19 | 2007-02-22 | Microbia, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
-
2004
- 2004-01-28 DE DE602004028678T patent/DE602004028678D1/de not_active Expired - Lifetime
- 2004-01-28 EP EP10170038A patent/EP2246360B1/de not_active Expired - Lifetime
- 2004-01-28 EP EP04706011A patent/EP1594517B1/de not_active Expired - Lifetime
- 2004-01-28 RU RU2005127058/15A patent/RU2353383C2/ru active
- 2004-01-28 NZ NZ570134A patent/NZ570134A/en not_active IP Right Cessation
- 2004-01-28 KR KR1020057013966A patent/KR101227626B1/ko active IP Right Grant
- 2004-01-28 RU RU2008147983/15A patent/RU2543350C2/ru active
- 2004-01-28 KR KR1020117019764A patent/KR101227627B1/ko active IP Right Grant
- 2004-01-28 SG SG2012003802A patent/SG192300A1/en unknown
- 2004-01-28 BR BR122018074353A patent/BR122018074353B8/pt active IP Right Grant
- 2004-01-28 PT PT04706011T patent/PT1594517E/pt unknown
- 2004-01-28 NZ NZ541595A patent/NZ541595A/en not_active IP Right Cessation
- 2004-01-28 CN CN2009102662250A patent/CN101787073B/zh not_active Expired - Lifetime
- 2004-01-28 DK DK10170038.3T patent/DK2246360T3/da active
- 2004-01-28 PT PT10170038T patent/PT2246360E/pt unknown
- 2004-01-28 DK DK04706011T patent/DK1594517T3/da active
- 2004-01-28 DK DK07011869.0T patent/DK1911763T3/da active
- 2004-01-28 AT AT04706011T patent/ATE365174T1/de active
- 2004-01-28 JP JP2006503109A patent/JP4584911B2/ja not_active Expired - Lifetime
- 2004-01-28 ES ES04706011T patent/ES2285417T3/es not_active Expired - Lifetime
- 2004-01-28 CA CA2514507A patent/CA2514507C/en not_active Expired - Lifetime
- 2004-01-28 DE DE602004007105T patent/DE602004007105T2/de not_active Expired - Lifetime
- 2004-01-28 SG SG200705302-8A patent/SG168407A1/en unknown
- 2004-01-28 MX MXPA05008097A patent/MXPA05008097A/es active IP Right Grant
- 2004-01-28 AT AT07011869T patent/ATE477268T1/de active
- 2004-01-28 BR BRPI0407071A patent/BRPI0407071B8/pt active IP Right Grant
- 2004-01-28 ES ES10170038T patent/ES2387848T3/es not_active Expired - Lifetime
- 2004-01-28 SI SI200430401T patent/SI1594517T1/sl unknown
- 2004-01-28 SI SI200431521T patent/SI1911763T1/sl unknown
- 2004-01-28 SI SI200431918T patent/SI2246360T1/sl unknown
- 2004-01-28 WO PCT/US2004/002390 patent/WO2004069165A2/en active Application Filing
- 2004-01-28 ES ES07011869T patent/ES2350123T3/es not_active Expired - Lifetime
- 2004-01-28 PT PT07011869T patent/PT1911763E/pt unknown
- 2004-01-28 EP EP07011869A patent/EP1911763B1/de not_active Expired - Lifetime
- 2004-01-28 CN CN200480008533A patent/CN100589839C/zh not_active Expired - Lifetime
- 2004-01-28 US US10/766,735 patent/US20040266989A1/en not_active Abandoned
- 2004-01-28 AU AU2004210161A patent/AU2004210161B2/en active Active
-
2005
- 2005-07-25 IL IL169863A patent/IL169863A/en active IP Right Grant
- 2005-08-18 NO NO20053864A patent/NO334112B1/no not_active IP Right Cessation
- 2005-11-23 HK HK05110618A patent/HK1078768A1/xx not_active IP Right Cessation
-
2007
- 2007-08-09 CY CY20071101072T patent/CY1110905T1/el unknown
- 2007-10-31 US US11/930,696 patent/US7704947B2/en not_active Expired - Lifetime
-
2009
- 2009-11-10 AU AU2009235993A patent/AU2009235993B2/en active Active
-
2010
- 2010-04-05 US US12/754,138 patent/US8080526B2/en not_active Expired - Lifetime
- 2010-06-22 JP JP2010141519A patent/JP5563384B2/ja not_active Expired - Lifetime
- 2010-11-04 CY CY20101101000T patent/CY1111058T1/el unknown
-
2012
- 2012-08-09 IL IL221380A patent/IL221380A0/en active IP Right Grant
- 2012-09-19 CY CY20121100859T patent/CY1113217T1/el unknown
-
2013
- 2013-02-28 JP JP2013038602A patent/JP5748791B2/ja not_active Expired - Lifetime
- 2013-04-05 NO NO20130460A patent/NO336768B1/no not_active IP Right Cessation
- 2013-05-22 HU HUS1300022 patent/HUS1300022I1/hu unknown
- 2013-05-22 LT LTPA2013013C patent/LTC1594517I2/lt unknown
- 2013-05-22 LU LU92200C patent/LU92200I2/fr unknown
- 2013-05-22 LU LU92201C patent/LU92201I2/fr unknown
- 2013-05-22 NL NL300593C patent/NL300593I2/nl unknown
- 2013-05-23 FR FR13C0029C patent/FR13C0029I2/fr active Active
- 2013-05-23 FR FR13C0030C patent/FR13C0030I1/fr active Active
- 2013-05-24 CY CY2013021C patent/CY2013021I1/el unknown
- 2013-05-24 BE BE2013C032C patent/BE2013C032I2/nl unknown
- 2013-05-24 CY CY2013022C patent/CY2013022I1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE477268T1 (de) | Zusammensetzungen zur behandlung von magen-darm- störungen | |
SG153824A1 (en) | Methods and compositions for the treatment of gastrointestinal disorders | |
WO2005016244A3 (en) | Methods and compositions for the treatment of gastrointestinal disorders | |
WO2007022531A3 (en) | Methods and compositions for the treatment of gastrointestinal disorders | |
WO2006086653A3 (en) | Methods and compositions for the treatment of gastrointestinal disorders | |
WO2007101158A3 (en) | Methods and compositions for the treatment of gastrointestinal disorders | |
WO2008002971A3 (en) | Methods and compositions for the treatment of gastrointestinal disorders | |
WO2005074575A3 (en) | Methods and compositions for the treatment of gastrointestinal disorders | |
EA201290799A1 (ru) | Лечение желудочно-кишечных расстройств | |
WO2007062168A3 (en) | Methods and compositions for the treatment of gastrointestinal disorders | |
IL171356A (en) | Anti-interferon receptor antibody for treatment of inflammatory bowel disease | |
DE502006006593D1 (de) | Verfahren zum nachweis von autoimmunantikörpern gegen den tsh-rezeptor und neue tsh- rezeptorchimären | |
CY1113569T1 (el) | Μεθοδοι και συνθεσεις για την αγωγη γαστρεντερικων διαταραχων |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1911763 Country of ref document: EP |